To 1HE EDITOR-Wade et al [1] reported a comparison of nalidixic acid plus nystatin with trimethoprim-sulfamethoxazole plus nystatin as prophylactic antibiotic regimens in patients with acute leukemias who were about to receive cytotoxic chemotherapy for remission induction. Although they found trimethoprim-sulfamethoxazole somewhat better than nalidixic acid in terms of infection prevention, they noted a statistically significant increase in filamentous fungal infections in patients receiving trimethoprim-sulfamethoxazole and increased duration of profound granulocytopenia during the initial remission in trimethoprim-sulfamethoxazole patients. I find it of interest to contrast this study with their previous study comparing prophylactic trimethoprim-sulfamethoxazole plus nystatin with oral gentamicin plus nystatin [2] (table 1).
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The earlier study appears to me to differ significantly from the more recent study only in that (1) trimethoprim-sulfamethoxazole was given twice a day compared with three times a day in the more recent study and (2) the more recent study included patients undergoing initial remission inductions as well as patients undergoing reinduction, while the previous study included only patients undergoing reinduction. It appears that the nalidixic acid group differs by having more women than men as well as by having fewer filamentous fungal infections than the other three groups. I wonder whether this sex difference might in some way be responsible for the apparent increased incidence of filamentous fungal infections in the trimethoprim-sulfamethoxazole group, either on the basis of some sex-linked susceptibility or resistance to fungal infections or possibly even an environmental factor that might increase the exposure of women patients to fungi. It would be useful to know the sex of patients who developed the significant filamentous fungal infections in both studies. It also appears to me that the conclusion that trimethoprim-sulfamethoxazole predisposed patients to fungal infections is questionable, since the rate of filamentous fungal infections in the trimethoprim-sulfamethoxazole group in the present study is the same as that seen in the previous study in both the trimethoprim-sulfamethoxazole and gentamicin groups. It would appear to be equally like-1171 ly that nalidixic acid in some way specifically prevented fungal infections or that the nalidixic acid group differed in some significant way from the trimethoprim-sulfamethoxazole group in the more recent study.
I wonder if the authors could provide details of the randomization which led to this difference in sex ratios and to the presence of six more patients in the trimethoprim-sulfamethoxazole group. The difference in sex ratios is unlikely to have occurred by chance (xl = 6.20; P < 0.02).
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'Io 1HE EDITOR -Dr Gurwith has raised two interesting points. The first is that the procedure used for randomization in our trial may have added a bias altering the final conclusions, and the second is that the increased frequency of filamentous fungal infections occurring among patients treated with trimethoprim-sulfamethoxazole may in some way be related to sex-linked susceptibility or resistance to fungal infections. As was stated in the Patients and Methods section of our report [1] , patients who had acute leukemia and who were to receive induction chemotherapy were stratified by disease status (that 
